N-ethyl-7-[(N-ethyl-4-fluoroanilino)methyl]-2-methyl-5-oxo-5H-[1,3]thiazolo[3,2-a]pyrimidine-3-carboxamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: N-ethyl-7-[(N-ethyl-4-fluoroanilino)methyl]-2-methyl-5-oxo-5H-[1,3]thiazolo[3,2-a]pyrimidine-3-carboxamide
• 英文别名: N-ethyl-7-((ethyl(4-fluorophenyl)amino)methyl)-2-methyl-5-oxo-5H-thiazolo[3,2-a]pyrimidine-3-carboxamide；N-ethyl-7-[(N-ethyl-4-fluoroanilino)methyl]-2-methyl-5-oxo-[1,3]thiazolo[3,2-a]pyrimidine-3-carboxamide
• 化学式: C₁₉H₂₁FN₄O₂S
• 分子量: 388.466
• InChiKey: VGSHGMJKSVXBDR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  27
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  90.3
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  2-氨基-5-甲基噻唑-4-甲酸甲酯 在 potassium carbonate 、 sodium iodide 作用下， 以 乙醇 、 乙腈 为溶剂， 反应 7.0h， 生成 N-ethyl-7-[(N-ethyl-4-fluoroanilino)methyl]-2-methyl-5-oxo-5H-[1,3]thiazolo[3,2-a]pyrimidine-3-carboxamide
  参考文献：
  名称：

  Discovery of GluN2A-Selective NMDA Receptor Positive Allosteric Modulators (PAMs): Tuning Deactivation Kinetics via Structure-Based Design

  摘要：

  The N-methyl-D-aspartate receptor (NMDAR) is a Na+ and Ca2+ permeable ionotropic glutamate receptor that is activated by the coagonists glycine and glutamate. NMDARs are critical to synaptic signaling and plasticity, and their dysfunction has been implicated in a number of neurological disorders, including schizophrenia, depression, and Alzheimer's disease. Herein we describe the discovery of potent GluN2A-selective NMDAR positive allosteric modulators (PAMs) starting from a high-throughput screening hit. Using structure-based design, we sought to increase potency at the GluN2A subtype, while improving selectivity against related amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPARs). The structure activity relationship of channel deactivation kinetics was studied using a combination of electrophysiology and protein crystallography. Effective incorporation of these strategies resulted in the discovery of GNE-0723 (46), a highly potent and brain penetrant GluN2A-selective NMDAR PAM suitable for in vivo characterization.

  DOI：

  10.1021/acs.jmedchem.5b02010

文献信息

• THIAZOLOPYRIMIDINONES AND METHODS OF USE THEREOF
  申请人：Genentech, Inc.

  公开号：US20160222033A1

  公开（公告）日：2016-08-04

  The present invention relates to certain thiazolopyrimidinone compounds, pharmaceutical compositions comprising such compounds, and methods of treatment using such compounds.

  本发明涉及某些噻唑嘧啶酮化合物、包含该类化合物的制药组合物以及使用该类化合物的治疗方法。
• Thiazolopyrimidinones and methods of use thereof
  申请人：Genentech, Inc.

  公开号：US10647731B2

  公开（公告）日：2020-05-12

  The present invention relates to certain thiazolopyrimidinone compounds, pharmaceutical compositions comprising such compounds, and methods of treatment using such compounds.

  本发明涉及某些噻唑并嘧啶酮化合物、包含此类化合物的药物组合物以及使用此类化合物进行治疗的方法。
• THIAZOLOPYRIMIDINONES AS MODULATORS OF NMDA RECEPTOR ACTIVITY
  申请人：F. Hoffmann-La Roche AG

  公开号：EP3055315B1

  公开（公告）日：2018-07-25
• US9988400B2
  申请人：——

  公开号：US9988400B2

  公开（公告）日：2018-06-05
• Discovery of GluN2A-Selective NMDA Receptor Positive Allosteric Modulators (PAMs): Tuning Deactivation Kinetics via Structure-Based Design
  作者：Matthew Volgraf、Benjamin D. Sellers、Yu Jiang、Guosheng Wu、Cuong Q. Ly、Elisia Villemure、Richard M. Pastor、Po-wai Yuen、Aijun Lu、Xifeng Luo、Mingcui Liu、Shun Zhang、Liang Sun、Yuhong Fu、Patrick J. Lupardus、Heidi J.A. Wallweber、Bianca M. Liederer、Gauri Deshmukh、Emile Plise、Suzanne Tay、Paul Reynen、James Herrington、Amy Gustafson、Yichin Liu、Akim Dirksen、Matthias G. A. Dietz、Yanzhou Liu、Tzu-Ming Wang、Jesse E. Hanson、David Hackos、Kimberly Scearce-Levie、Jacob B. Schwarz

  DOI：10.1021/acs.jmedchem.5b02010

  日期：2016.3.24

  The N-methyl-D-aspartate receptor (NMDAR) is a Na+ and Ca2+ permeable ionotropic glutamate receptor that is activated by the coagonists glycine and glutamate. NMDARs are critical to synaptic signaling and plasticity, and their dysfunction has been implicated in a number of neurological disorders, including schizophrenia, depression, and Alzheimer's disease. Herein we describe the discovery of potent GluN2A-selective NMDAR positive allosteric modulators (PAMs) starting from a high-throughput screening hit. Using structure-based design, we sought to increase potency at the GluN2A subtype, while improving selectivity against related amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPARs). The structure activity relationship of channel deactivation kinetics was studied using a combination of electrophysiology and protein crystallography. Effective incorporation of these strategies resulted in the discovery of GNE-0723 (46), a highly potent and brain penetrant GluN2A-selective NMDAR PAM suitable for in vivo characterization.